Bladder Tumor Heterogeneity: The Impact on Clinical Treatment

被引:16
作者
Chen, Chao [1 ,2 ]
Qi, Xiang Jie [3 ]
Cao, Yan Wei [1 ,2 ]
Wang, Yong Hua [1 ,2 ]
Yang, Xue Cheng [1 ,2 ]
Shao, Shi Xiu [1 ,2 ]
Niu, Hai Tao [1 ,2 ]
机构
[1] Qingdao Univ, Affiliated Hosp, Dept Urol, Qingdao 266101, Peoples R China
[2] Key Lab Urol, Qingdao, Peoples R China
[3] Peoples Hosp Linzi Dist, Dept Urol, Zibo, Shandong, Peoples R China
基金
中国国家自然科学基金;
关键词
Tumor heterogeneity; Bladder cancer; Personalized medicine; Therapy; CANCER STEM-CELL; GENETIC-HETEROGENEITY; CLONAL EVOLUTION; DRUG-RESISTANCE; SIDE POPULATION; MUTATIONS; INSTABILITY; GRADE; PREVALENCE; BIOLOGY;
D O I
10.1159/000370165
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Bladder cancer relapse and treatment failure in most patients have often been attributed to chemoresistance in tumor cells and metastasis. Emerging evidence indicates that tumor heterogeneity may play an equally important role and extends to virtually all measurable properties of cancer cells. Although the idea of tumor heterogeneity is not new, little attention has been paid to applying it to understand and control bladder cancer progression. With the development of biotechnology, such as Gene sequencing, recent advances in understanding its generation model, original basis, consequent problems, and derived therapies provide great potential for tumor heterogeneity to be considered a new insight in the treatment of bladder cancers. (C) 2015 S. Karger AG, Basel
引用
收藏
页码:1 / 8
页数:8
相关论文
共 50 条
  • [11] The Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor
    Hayakawa, Nozomi
    Kikuchi, Eiji
    Mikami, Shuji
    Matsumoto, Kazuhiro
    Miyajima, Akira
    Oya, Mototsugu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (03) : 424 - 429
  • [12] Precision medicine and bladder cancer heterogeneity
    Ma, Guofeng
    Yang, Xuecheng
    Liang, Ye
    Wang, Liping
    Li, Dan
    Chen, Yuanbin
    Liang, Zhijuan
    Wang, Yonghua
    Niu, Haitao
    BULLETIN DU CANCER, 2018, 105 (10) : 925 - 931
  • [13] Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications
    de Bruin, Elza C.
    Taylor, Tiffany B.
    Swanton, Charles
    GENOME MEDICINE, 2013, 5
  • [14] Tumor heterogeneity and cancer stem cell paradigm: Updates in concept, controversies and clinical relevance
    Singh, Anup Kumar
    Arya, Rakesh Kumar
    Maheshwari, Shrankhla
    Singh, Akhilesh
    Meena, Sanjeev
    Pandey, Priyanka
    Dormond, Olivier
    Datta, Dipak
    INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (09) : 1991 - 2000
  • [15] Evolving concepts of tumor heterogeneity
    Zellmer, Victoria R.
    Zhang, Siyuan
    CELL AND BIOSCIENCE, 2014, 4
  • [16] Capturing tumor heterogeneity and clonal evolution in solid cancers using circulating tumor DNA analysis
    Perdigones, Nieves
    Murtaza, Muhammed
    PHARMACOLOGY & THERAPEUTICS, 2017, 174 : 22 - 26
  • [17] The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment
    Li, Ding
    Finley, Stacey D.
    INTEGRATIVE BIOLOGY, 2018, 10 (04) : 253 - 269
  • [18] A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration
    Schurch, Christian M.
    Rasche, Leo
    Frauenfeld, Leonie
    Weinhold, Niels
    Fend, Falko
    VIRCHOWS ARCHIV, 2020, 476 (03) : 337 - 351
  • [19] Pathological Bases and Clinical Impact of Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma
    Lopez, Jose I.
    Angulo, Javier C.
    CURRENT UROLOGY REPORTS, 2018, 19 (01)
  • [20] Tumor grade heterogeneity in urothelial bladder carcinoma -: Proposal of a system using combined numbers
    Billis, A
    Carvalho, RB
    Mattos, AC
    Negretti, F
    Nogueira, CR
    Oliveira, MCBM
    Valenca, JT
    Adam, RL
    Cotta, ACS
    Nunes, MS
    Dinamarco, PVV
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2001, 35 (04): : 275 - 279